Trials / Unknown
UnknownNCT01852435
R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3B
A Multi-center, Prospective, Randomized Phase III Study of the Safety and Efficacy of R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3B
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 648 (actual)
- Sponsor
- Ruijin Hospital · Academic / Other
- Sex
- All
- Age
- 16 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the safety and efficacy of R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell lymphoma and Follicular Lymphoma Grade 3B patients.
Detailed description
The study aims to evaluate the safety and efficacy of R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell lymphoma and Follicular Lymphoma Grade 3B patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | R-CEOP-70 | |
| DRUG | R-CEOP-90 | |
| DRUG | R-CHOP-50 |
Timeline
- Start date
- 2013-05-01
- Primary completion
- 2017-12-01
- Completion
- 2018-02-01
- First posted
- 2013-05-13
- Last updated
- 2017-11-14
Locations
12 sites across 1 country: China
Source: ClinicalTrials.gov record NCT01852435. Inclusion in this directory is not an endorsement.